Cadence Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Cadence Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-36,821	Closed	-$1.15M	–	697
2017 Q1	$1.15M	Sell	36,821 -14,315	-28%	-$384K	0.08%	304
2016 Q4	$1.29M	Sell	51,136 -2,351	-4%	-$52.5K	0.09%	277
2016 Q3	$1.32M	Buy	53,487 +3,227	+6%	+$73K	0.1%	248
2016 Q2	$1.02M	Sell	50,260 -1,105	-2%	-$19.6K	0.08%	285
2016 Q1	$783K	Sell	51,365 -8,780	-15%	-$115K	0.06%	363
2015 Q4	$808K	Buy	60,145 +10,917	+22%	+$169K	0.05%	361
2015 Q3	$691K	Buy	+49,228	New	+$915K	0.05%	398
2015 Q2	–	Sell	-111,020	Closed	-$1.34M	–	662
2015 Q1	$1.34M	Buy	111,020 +1,030	+0.9%	+$9.73K	0.08%	315
2014 Q4	$913K	Buy	+109,990	New	+$924K	0.05%	429

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Cadence Capital Management's SUPN Position: Q2 2017 in Review

Cadence Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 36,821 shares — an estimated $1.15M sold.

Cadence Capital Management first reported a position in SUPN in Q4 2014 and held it in 9 quarters. The position peaked at $1.34M in Q1 2015. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

Cadence Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Cadence Capital Management sold 36,821 Supernus Pharmaceuticals shares in Q2 2017, an estimated $1.15M.
Cadence Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Cadence Capital Management's Supernus Pharmaceuticals position peaked at $1.34M in Q1 2015.
265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Cadence Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.